Yep! Listening to the video shared of Sergio stating the new structure of remuneration tied to performance.
It really feels like this is a new company, with a new name and embarking on a fully funded Ph2 trial with a new objective in being a neurological pharmaceutical across multiple disorders.
People looking to turn a quick buck are leaving but for those who have invested in bio stocks before (NEU, DXB) for me, you understand it takes time to realise true value.
When positive news starts to drop, you start seeing 30-50% days.
Phase II Begins, Cashed Up with Healey In the Sights of Big Pharma $$$, page-319
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $80.25M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.3¢ | $89.46K | 536.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 287162 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 17500 | 1 |
View Market Depth
| Last trade - 13.45pm 17/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |